Thrivent Financial for Lutherans raised its holdings in Heska Corp (NASDAQ:HSKA) by 5.2% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 5,904 shares of the medical research company’s stock after acquiring an additional 294 shares during the period. Thrivent Financial for Lutherans owned approximately 0.06% of Heska worth $326,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in HSKA. Envestnet Asset Management Inc. grew its position in shares of Heska by 22.7% in the fourth quarter. Envestnet Asset Management Inc. now owns 5,699 shares of the medical research company’s stock valued at $547,000 after purchasing an additional 1,053 shares in the last quarter. BNP Paribas Arbitrage SA boosted its stake in Heska by 78.1% during the first quarter. BNP Paribas Arbitrage SA now owns 2,804 shares of the medical research company’s stock worth $155,000 after buying an additional 1,230 shares during the last quarter. Barclays PLC grew its holdings in Heska by 13.2% in the 4th quarter. Barclays PLC now owns 10,513 shares of the medical research company’s stock valued at $1,009,000 after buying an additional 1,227 shares in the last quarter. State Street Corp increased its stake in shares of Heska by 1.2% in the 1st quarter. State Street Corp now owns 287,309 shares of the medical research company’s stock worth $15,888,000 after acquiring an additional 3,430 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Heska by 1,858.8% during the 1st quarter. JPMorgan Chase & Co. now owns 46,267 shares of the medical research company’s stock worth $2,558,000 after acquiring an additional 43,905 shares during the period. 79.78% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ:HSKA opened at $91.16 on Wednesday. Heska Corp has a 52 week low of $50.00 and a 52 week high of $110.90. The stock’s fifty day moving average is $85.53 and its two-hundred day moving average is $85.34. The stock has a market capitalization of $843.77 million, a price-to-earnings ratio of -91.16 and a beta of 1.72. The company has a quick ratio of 9.89, a current ratio of 11.21 and a debt-to-equity ratio of 0.19.
Heska (NASDAQ:HSKA) last posted its earnings results on Thursday, May 7th. The medical research company reported ($0.70) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.44). Heska had a negative return on equity of 1.04% and a negative net margin of 5.99%. The firm had revenue of $30.65 million for the quarter, compared to analyst estimates of $33.47 million. On average, sell-side analysts expect that Heska Corp will post -0.81 EPS for the current fiscal year.
Several equities research analysts recently issued reports on HSKA shares. Zacks Investment Research cut shares of Heska from a “buy” rating to a “hold” rating in a research report on Tuesday. BidaskClub raised shares of Heska from a “hold” rating to a “buy” rating in a research report on Tuesday, May 12th. Sidoti decreased their price objective on Heska from $77.00 to $59.00 and set a “neutral” rating on the stock in a report on Friday, March 27th. Piper Sandler cut their target price on Heska from $107.00 to $87.00 in a research note on Monday, May 25th. Finally, TheStreet lowered Heska from a “c-” rating to a “d+” rating in a research note on Friday, April 3rd. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $81.67.
In other news, CEO Kevin S. Wilson sold 6,234 shares of the stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $87.09, for a total value of $542,919.06. Following the sale, the chief executive officer now directly owns 104,955 shares in the company, valued at $9,140,530.95. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Kevin S. Wilson sold 3,266 shares of Heska stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $85.00, for a total value of $277,610.00. Following the completion of the transaction, the chief executive officer now owns 104,955 shares of the company’s stock, valued at $8,921,175. The disclosure for this sale can be found here. Insiders have sold 30,941 shares of company stock worth $2,741,842 in the last three months. Corporate insiders own 11.70% of the company’s stock.
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.
Further Reading: What does an equal weight rating mean?
Want to see what other hedge funds are holding HSKA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heska Corp (NASDAQ:HSKA).
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.